EP 12B: Management of Chemotherapy Induced Myelosuppression (CIM) in ES-SCLC
In this companion article, Dr Luis Raez provides insights into effective management patients with extensive-stage small cell lung cancer who develop chemotherapy-induced myelosuppression.
Realizing the Promise of Biomarker Testing in Lung Cancer and Beyond
Luis E. Raez, MD, FACP, FCCP, immediate past president of Florida Society of Clinical Oncology, evaluates the role of biomarker testing for lung cancer and other disease types.
EP 12A: Managing Thrombocytopenia in Patients receiving Chemotherapy for ES-SCLC
Dr Luis Raez shares his perspectives on ways to manage thrombocytopenia in patients receiving chemotherapy for ES-SCLC treatment.
TRK Inhibition Continues to Advance the Lung Cancer Field
Luis E. Raez, MD, discusses the treatment of TRK fusion-positive lung cancers in the past and the present.
Larotrectinib: A Tumor-Agnostic Therapy
Treatment Resistance Due to Gene Mutation
Management of Toxicities of Larotrectinib
Response to Treatment With Larotrectinib
Larotrectinib in NTRK Fusion-Positive Lung Cancer
Targeted Treatment in NTRK Fusion-Positive Cancer
Treatment in NTRK Fusion-Positive Lung Cancer
Testing in NTRK Fusion-Positive Lung Cancer
Case of an NTRK Fusion-Positive Lung Cancer Patient
A 67-Year-Old Man With NTRK Fusion-Positive Metastatic Lung Cancer
Luis Raez, MD, reviews the case of a 67-year-old man with metastatic non-small cell NTRK gene fusion lung cancer.
Options for Patients With Lung Cancer and Genetic Alterations
Luis E. Raez, MD, discusses targeted therapies for patients with lung cancer who have genetic alterations.
